Latest drug developments in the field of cardiovascular disease

International Journal of Angiology

Volumn 19, Issue 3, 2010, Pages

  Stern, Craig S ^a,b   Lebowitz, Jason ^a,b  

^a Pro Pharma Pharmaceutical Consultants Inc   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Clinical trials; Drug development; Drug pipeline; Drugs; Models; New approvals

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AVE 9488; BETRIXABAN; BUDIODARONE; CARDIOVASCULAR AGENT; CHOLINE FENOFIBRATE; CLOPIDOGREL; DABIGATRAN ETEXILATE; DARAPLADIB; DOFETILIDE; DRONEDARONE; ENDEAVOR; ENOXAPARIN; EVEROLIMUS; FENOFIBRIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MK 0524A; MK 0524B; PACLITAXEL; PLACEBO; PRASUGREL; PRT 54021; RIVAROXABAN; ROSUVASTATIN; SOTALOL; TICAGRELOR; TICLOPIDINE; TSE 4208; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORAPAXAR; WARFARIN; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; GENE EXPRESSION; GENE THERAPY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LIVER DISEASE; LOADING DRUG DOSE; LUNG DISEASE; LUNG EMBOLISM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATENT; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 80053001352     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1278379     Document Type: Review

References (25)

1. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627-36.
2. Jones PH, Bays HE, Davidson MH, et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: Study design and rationale of a phase III clinical programme. Clin Drug Investig 2008;28:625-34.
3. Bui QT, Wilensky RL. Darapladib. Expert Opin Investig Drugs 2010;19:161-8.
4. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-5.
5. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605.
6. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: Study design and rationale. Am Heart J 2009;58:327-334.e4.
7. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75. (Pubitemid 351930851)
8. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86. (Pubitemid 351930852)
9. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
10. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. (Pubitemid 350106708)
11. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6. (Pubitemid 350017792)
12. Cannon CP, Husted S, Harrington RA, et al; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-51. (Pubitemid 350007959)
13. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
14. Kush D, Hu DY, Ye P, et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology 2009;114:192-8.
15. Shah S, Ceska R, Gil-Extremera B, et al. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2010;64:727-38.
16. Davy JM, Herold M, Hoglund C, et al; ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: The Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527.e1-9.
17. Hohnloser SH, Crijns HJ, van Eickels M, et al; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78.
18. Koøber L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87. (Pubitemid 351860860)
19. Dale KM, White CM. Dronedarone: An amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 2007;41:599-605. (Pubitemid 46625482)
20. Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-99. (Pubitemid 47367078)
21. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol 2009;193:25-58.
22. Torre-Amione G, Bourge RC, Colucci WS, et al. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: The ACCLAIM trial rationale and design. Can J Cardiol 2007;23:369-76. (Pubitemid 46908311)
23. Torre-Amione G, Anker SD, et al. Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): A placebo-controlled randomised trial. Lancet 2008;371:228-36.
24. Vos MA. Atrial-specific drugs: The way to treat atrial fibrillation. J Cardiovasc Electrophysiol 2004;15:1451-2. (Pubitemid 40013679)
25. Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: An emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol 2006;17:S17-S20. (Pubitemid 44166635)